ProTEct-MS Phase 2 trial confirms safety of higher doses of temelimab and synergistic potential to address neurodegeneration on top of anti-inflammatory treatment in multiple sclerosis

Geneva, Switzerland, March 21, 2022 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis, today announced that the top-line results of the ProTEct-MS study confirm the excellent safety profile and tolerability of higher doses […]